Baron D, Drugeon H, Nicolas F, Courtieu A
Eur J Intensive Care Med. 1976 Sep;2(2):89-96. doi: 10.1007/BF01886122.
Tobramycin was used in the treatment of 35 severe infections. Its clinical effectiveness was confirmed in broncho-pulmonary infections without septicemia and in septicemia without lung involvement. Poor results were obtained in septicemia where the initial site 9 infection was in the lungs. This antibiotic appeared as a very good antistaphylococcal agent. In vitro superiority over gentamicin against Pseudomonas was not be confirmed clinically. Tobramycin deserves to be administered initially in serious infections because of the possibility that the causative organism might be a gentamicin-resistant, tobramycin susceptible strain. Three such cases were observed in our 35 patients. This susceptibility dissociation in favor of tobramycin was demonstrated in two strains of Klebsiella and one strain of Enterobacter. A dosage regimen in patients with impaired renal function is proposed. It requires confirmation.
妥布霉素用于治疗35例严重感染。其临床疗效在无败血症的支气管肺部感染以及无肺部受累的败血症中得到证实。在初始感染部位为肺部的败血症中，效果不佳。这种抗生素似乎是一种非常好的抗葡萄球菌药物。在临床上未证实其在体外对假单胞菌的优越性优于庆大霉素。由于致病微生物可能是对庆大霉素耐药但对妥布霉素敏感的菌株，因此在严重感染中最初值得使用妥布霉素。在我们的35例患者中观察到3例此类病例。在两株克雷伯菌属和一株肠杆菌属中证实了这种有利于妥布霉素的敏感性分离。提出了肾功能受损患者的给药方案。这需要进一步证实。
